TKT and glioma: Most recently, a combination of adenoviral vectors Ad-hCMV-TK “Ad-TK” and Ad-hCMV-FLT3L used to treat glioma patients was able to induce a significant influx of intratumoral CD8 T cells and pDCs, a finding not seen in prior studies using only Ad-TK (159).